Therapeutic Plasma Exchange (TPE) for Aging

Verdict: Suggestive (preclinical / small clinical pilots) → likely high-variance trajectory Last reviewed: 2026-04-25 Triangulated against anchor: Senolytics (Suggestive) — both preclinically promising, early human, expensive

TL;DR

TPE (and related approaches: parabiosis, "young plasma," albumin replacement) emerged from the parabiosis literature showing systemic factors influence aging. Several small human pilots (Conboy, Thirsky, Alkahest spinouts) have produced suggestive but inconclusive biomarker effects; one Conboy 2020 paper showed promising age-marker reductions. The interventions are expensive, time-intensive, not standardized, and lack rigorous large RCT evidence. Verdict: Suggestive with substantial uncertainty in either direction.

What it is

A blood-based intervention category including:

• Therapeutic plasma exchange — replacing plasma with albumin solution (akin to clinical TPE for autoimmune disease)
• "Young plasma" infusion — Ambrosia-style infusions of young donor plasma; controversial and largely commercially driven before regulatory pushback
• Albumin / IVIG combinations — Conboy lab approach
• Plasma fractionation products — Alkahest's GRF6021 etc., now mostly discontinued in their original aging program

Costs range from thousands to tens of thousands per treatment course; protocols are not standardized.

Proposed mechanism

• Parabiosis (joining young + old animals' circulation) showed systemic anti-aging effects from young blood — established in mice (Conboy, Wagers, Rando labs).
• Subsequent work suggests removing aging factors (dilution / replacement) may matter more than adding youth factors.
• Specific candidate factors: GDF11 (controversial), TIMP-2, β2-microglobulin, etc. — none are individually established.

Confidence: Established for the parabiosis biology; Plausible for translation via plasma manipulation; Hypothetical for clinically meaningful aging benefit.

Evidence ladder

Animal models (T3-T4)

• Parabiosis mouse studies are foundational and well-replicated; multiple labs.
• Specific factor studies (GDF11, etc.) are more contested.
• Lifespan effects in parabiosis models documented but parabiosis itself isn't translatable.

Human (T2)

• Conboy et al. — small pilot trials of plasma exchange / albumin replacement showed reductions in inflammatory markers and some age-related biomarkers in small samples.
• Ambrosia "young plasma" — commercial infusion clinic, FDA pushback in 2019; never produced rigorous trial data.
• Alkahest / GRF6021 — Phase 2 trials in mild-to-moderate Alzheimer's: largely null on cognitive endpoints; aging program subsequently de-emphasized.
• No mortality or healthspan RCT at scale.

Confounds

• Trial heterogeneity — TPE protocols, plasma sources, and dosing vary widely; comparing trials is fraught.
• Blinding difficulty — sham plasma exchange is technically possible but not always done.
• Selection — self-selecting patients in commercial infusion clinics differ in many ways.
• Specific-factor claims have not held up — the field has moved away from "find the youth factor" toward "dilute the aging factors."

Conflict of interest scan

• Substantial commercial layering: Ambrosia, Alkahest (acquired/spun out), various clinics offering TPE for aging.
• Academic Conboy lab work is independent.
• Net: substantial discount on commercial-clinic claims; the academic literature is real but small.

Human translation

Honest read: Parabiosis biology is real; the human translation is at a very early stage with mostly biomarker-level evidence. The commercial market has moved faster than the science. For someone considering TPE for aging at a clinic: the evidence base does not support the cost, and protocols are non-standardized. The academic case is interesting and worth tracking but premature for personal use.

Calibrated verdict

Suggestive. Per methodology, T3-T4 animal evidence with replication, human data early/mixed. Falls into Suggestive band. Substantial commercial entanglement makes the popular discourse less reliable than the academic evidence.

Compared to senolytics (Suggestive), plasma exchange has less mature human RCT evidence and more commercial layering. Both are at Suggestive but senolytics has more clinical translation in motion.

Compared to HBOT (Mixed), plasma exchange has stronger animal-model foundation but similar single-group / small-trial concerns at the human level.

Confidence interval on verdict

• Could move to Probable with rigorous, larger placebo-controlled TPE trials reading positive on validated biomarkers.
• Could move to Mostly hype if Alkahest-pattern null results dominate the next round of trials.
• High variance on the trajectory; ~2-3 year horizon for clarity.

Open questions

• Q: Is the Conboy "neutral plasma exchange" approach being scaled into a larger pre-registered RCT?
• Q: Which aging biomarkers are reliably modified by TPE, and do those biomarkers predict outcomes?
• Q: For non-aging-related TPE indications (e.g., autoimmune), are there long-term observational signals on age-related disease?
• Q: What is the minimum effective protocol — single session, monthly, quarterly?

Sources

• Conboy lab parabiosis publications (Berkeley) and follow-up plasma dilution work
• Alkahest GRF6021 Alzheimer's program publications and outcomes
• Ambrosia controversy and FDA response (2019, public reporting)

Produced under methodology locked 2026-04-24. Triangulated against senolytics anchor.